Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODAC To Assess Safety Of Lilly’s Evista As Breast Cancer Preventative

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is seeking advice from its Oncologic Drugs Advisory Committee on expectations for efficacy and risk when dealing with a drug to prevent breast cancer.

You may also be interested in...



ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative

Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.

ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative

Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.

Lilly Will Add 40% Capacity To Diabetes Sales Force In Q1

Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel